低分子肝素治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者的临床效果  

Clinical Efficacy of Low Molecular Weight Heparin in the Treatment of COPD with TypeⅡRespiratory Failure

作　　者：刘石磊 LIU Shilei(Department of Respiratory,the Second people's Hospital,Liaoyang,China 111000)

机构地区：[1]辽宁省辽阳市第二人民医院呼吸二科,辽宁辽阳111000

出　　处：《中国医药指南》2022年第7期42-45,共4页Guide of China Medicine

摘　　要：目的关于低分子肝素治疗慢性阻塞性肺疾病(COPD)合并Ⅱ型呼吸衰竭的临床效果。方法本文行分组对照试验,将2018年2月至2019年10月收治的50例COPD合并Ⅱ型呼吸衰竭患者应用抽签法则分为观察组和对照组,均为25例。观察组行低分子肝素+呼吸兴奋剂尼可刹米治疗,对照组行呼吸兴奋剂尼可刹米治疗,统计两组患者经过不同治疗之后的有效率、并发症发生率、治疗前后的肺功能指标、生活质量,治疗以后的满意度等,并对相关数据进行统计学比较。结果①观察组(23例,占92.00%)经过低分子肝素用药后的治疗有效率明显比对照组(17例,占68.00%)单纯用药呼吸兴奋剂尼可刹米更高,差异有统计学意义(P<0.05)。②观察组(1例,占4.00%)联合低分子肝素用药后的并发症发生率相比对照组(9例,占36.00%)单纯用药呼吸兴奋剂尼可刹米更低,差异有统计学意义(P<0.05)。③治疗前,两组患者的FEV_(1)、FEV_(1)/FVC和PEF等差异没有显著性(P>0.05),治疗后,两组的FEV_(1)、FEV_(1)/FVC和PEF都得到改善,但观察组的改善更为显著,差异有统计学意义(P<0.05)。④治疗前,两组患者的SF-36量表评分之间的差异不显著(P>0.05),治疗后,两组患者的SF-36量表评分均有所改善,但观察组患者的改善更为突出,差异有统计学意义(P<0.05)。⑤观察组(24例,占96.00%)经低分子肝素联合用药后的患者满意度比对照组(17例,占68.00%)单纯用药呼吸兴奋剂尼可刹米更高,差异有统计学意义(P<0.05)。结论针对COPD合并Ⅱ型呼吸衰竭的患者在常规用药呼吸兴奋剂尼可刹米基础之上联合低分子肝素用药可以使治疗总有效率得到提升,还能降低患者因病而出现的各类并发症,调节患者的肺功能各项指标,使患者的生活质量得到好转,能提升整体满意程度,值得推荐。Objective To evaluate the clinical efficacy of low molecular weight heparin in the treatment of chronic obstructive pulmonary disease(COPD)with typeⅡrespiratory failure.Methods A grouped controlled trial was conducted in this study,and 50 patients with COPD combined with typeⅡrespiratory failure who were treated from February 2018 to October 2019 were divided into an observation group and a control group by drawing lots,with 25 cases in each group.The observation group was treated with low molecular weight heparin+respiratory stimulant nicotide,and the control group was treated with the respiratory stimulant nicotamide.Indicators,quality of life,satisfaction after treatment,etc.,and related data were statistically compared.Results(1)The effective rate of the observation group(23 cases,accounting for 92.00%)treated with low molecular weight heparin was significantly higher than that of the control group(17 cases,accounting for 68.00%),and the difference was statistically significant(P<0.05).(2)The incidence of complications in the observation group(1 case,accounting for 4.00%)combined with low molecular weight heparin was compared with the control group(9 cases,accounting for 36.00%)alone The respiratory stimulant nicotamide was lower,and the difference was statistically significant(P<0.05).(3)Before treatment,there was no significant difference in FEV_(1),FEV_(1)/FVC and PEF between the two groups(P>0.05),after treatment,the FEV_(1),FEV_(1)/FVC and PEF of the two groups were improved,but the improvement in the observation group was more significant,and the difference was statistically significant(P<0.05).(4)Before treatment,there was no significant difference between the SF-36 quality of life scale scores between the two groups(P>0.05).After treatment,the SF-36 quality of life scale scores of the two groups were improved,but the observation group patients had The improvement was more prominent,and the difference was statistically significant(P<0.05).(5)The patients in the observation group(24 cases,accounting

关 键 词：慢性阻塞性肺疾病 Ⅱ型呼吸衰竭 低分子肝素 肺功能 并发症 生活质量 

分 类 号：R563[医药卫生—呼吸系统]